Menu
  • Join
  • Login
  • Contact
 

Search abstracts


NIVOLUMAB-INDUCED FULMINANT TYPE 1 DIABETES

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Portugal)
  • Co-author(s): Carolina Lopes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
    Sandra Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
    Manuel Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal;School of Health Sciences, Polytechnic Institute of Guarda, Guarda, Portugal
  • Abstract:

    Background

    Nivolumab is an immune checkpoint inhibitor (ICI) that binds and blocks the activation of PD-1’s receptor, reactivating T cells and cell-mediated immune responses. Fulminant type 1 diabetes (FD) is an immune endocrinopathy resulting from a violent immune attack which leads to complete destruction of pancreatic β-cells. FD can happen as..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses